Search

Your search keyword '"Justement JS"' showing total 63 results

Search Constraints

Start Over You searched for: Author "Justement JS" Remove constraint Author: "Justement JS"
63 results on '"Justement JS"'

Search Results

1. Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse.

2. Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir.

3. Timing of antiretroviral therapy initiation affects intact HIV reservoirs following analytical treatment interruption.

4. Immunologic and Virologic Parameters Associated With Human Immunodeficiency Virus (HIV) DNA Reservoir Size in People With HIV Receiving Antiretroviral Therapy.

5. Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV.

7. Impact of Monkeypox Virus Infection on Immune Parameters in a Woman With Human Immunodeficiency Virus Receiving Clinically Effective Antiretroviral Therapy.

9. Effect of aging on immune cells in male HIV-infected and -uninfected healthy individuals.

10. Effect of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Booster on Human Immunodeficiency Virus Reservoirs and Immune Markers.

11. A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings.

12. Combination anti-HIV antibodies provide sustained virological suppression.

13. Correlation Between TIGIT Expression on CD8+ T Cells and Higher Cytotoxic Capacity.

14. Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy.

15. Kinetics of Plasma HIV Rebound in the Era of Modern Antiretroviral Therapy.

16. Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals.

17. An open-label phase 1 clinical trial of the anti-α 4 β 7 monoclonal antibody vedolizumab in HIV-infected individuals.

18. Impact of Treatment Interruption on HIV Reservoirs and Lymphocyte Subsets in Individuals Who Initiated Antiretroviral Therapy During the Early Phase of Infection.

19. IgG3 regulates tissue-like memory B cells in HIV-infected individuals.

20. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals.

21. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection.

22. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

23. Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral Burdens.

24. A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned.

25. Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir.

26. Glycosylation, hypogammaglobulinemia, and resistance to viral infections.

27. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.

28. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy.

29. Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy.

30. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy.

31. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.

32. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.

33. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.

34. Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells.

35. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.

36. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily.

37. Relationship between the frequency of HIV-specific CD8+ T cells and the level of CD38+CD8+ T cells in untreated HIV-infected individuals.

38. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals.

39. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy.

40. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.

41. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.

42. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes.

43. Interleukin-6 and glucocorticoids synergistically induce human immunodeficiency virus type-1 expression in chronically infected U1 cells by a long terminal repeat independent post-transcriptional mechanism.

44. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.

45. Increased in vitro tetanus-induced production of HIV type 1 following in vivo immunization of HIV type 1-infected individuals with tetanus toxoid.

46. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1.

47. Glucocorticoids synergize with tumor necrosis factor alpha in the induction of HIV expression from a chronically infected promonocytic cell line.

48. Interferon gamma induces the expression of human immunodeficiency virus in persistently infected promonocytic cells (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells.

49. CD34+ bone marrow cells are infected with HIV in a subset of seropositive individuals.

50. Retinoic acid mimics transforming growth factor beta in the regulation of human immunodeficiency virus expression in monocytic cells.

Catalog

Books, media, physical & digital resources